GlassScriptPhysician profile
Catherine S Riggan
NPI 1427026202
$1,668.72
in general payments reported to CMS, 2019-2025
19 companies · $115 in 2025
The $115 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $111 · 2021: $225 · 2022: $226 · 2023: $281 · 2024: $394 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $371.19 | 2019-2024 | Jornay Pm |
| Corium, LLC | $285.97 | 2021-2024 | Azstarys |
| Cranial Technologies, INC | $231.16 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $184.67 | 2019-2024 | Bexsero |
| Pfizer INC. | $180.73 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $92.05 | 2021-2022 | |
| Adlon Therapeutics L.P. | $51.19 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.54 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $32.98 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $27.10 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $23.35 | 2025 | Vaxelis, Rotateq, Enflonsia |
| Neos Therapeutics, LP | $23.33 | 2022 | |
| Genentech USA, INC. | $23.06 | 2019 | |
| Kyowa Kirin, INC. | $22.80 | 2024 | Crysvita |
| Tris Pharma INC | $18.73 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $17.37 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.14 | 2025 | Jornay Pm |
| Shire North American Group INC | $14.17 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.19 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Riggan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.